Advertisement

Pharmacology & Biotechnology

  • Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy
    Open Access
    Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy

    Christopher R Heier, Qing Yu, Alyson A Fiorillo, Christopher B Tully, Asya Tucker, Davi A Mazala, Kitipong Uaesoontrachoon, Sadish Srinivassane, Jesse M Damsker, Eric P Hoffman, Kanneboyina Nagaraju, Christopher F Spurney

    Christopher R Heier ... Christopher F Spurney

    Published 11 February 2019

    Vamorolone is a first-in-class dissociative drug that selectively targets the glucocorticoid receptor to safely treat chronic inflammation and the mineralocorticoid receptor to treat cardiomyopathy, providing efficacy with improved safety in mouse models of Duchenne muscular dystrophy.

Advertisement